期刊
ANNALES D ENDOCRINOLOGIE
卷 79, 期 5, 页码 591-595出版社
MASSON EDITEUR
DOI: 10.1016/j.ando.2018.07.005
关键词
Immunotherapy; Tyrosine kinase inhibitors; MTOR inhibitors; Dysthyroidism; Hypophysitis; Diabetes; Dyslipidemia; Adrenal failure
The present final consensus statement of the French Society of Endocrinology lays out the assessments that are to be systematically performed before and during anticancer treatment by immunotherapy, tyrosine kinase inhibitors or mTOR inhibitors, even without onset of any endocrinopathy. It also discusses the CTCAE adverse event grading system in oncology and the difficulty of implementing it for endocrine side-effects of these anticancer treatments. Notably, this is why certain treatment steps applied in other side-effects (e.g., high-dose corticosteroids, contraindications to immunotherapy, etc.) need to be discussed before implementation for endocrine side-effects. (C) 2018 Elsevier Masson SAS. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据